Systemic isotretinoin therapy in the era of COVID-19
- PMID: 32358858
- PMCID: PMC7261989
- DOI: 10.1111/dth.13482
Systemic isotretinoin therapy in the era of COVID-19
Comment in
-
Isotretinoin in acne treatment during the coronavirus disease 2019 (COVID-19): A retrospective analysis of adherence to therapy and side effects.Dermatol Ther. 2021 Jan;34(1):e14677. doi: 10.1111/dth.14677. Epub 2020 Dec 22. Dermatol Ther. 2021. PMID: 33320409 Free PMC article. No abstract available.
References
-
- Abdelmaksoud A, Lotti T, Anadolu R, et al. Low dose of isotretinoin: a comprehensive review. Dermatol Ther. 2020;33(2):e13251. - PubMed
-
- Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID‐19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16‐23years outside Wuhan and characteristics of young patients with COVID‐19: a prospective contact‐tracing study. J Infect. 2020. 10.1016/j.jinf.2020.03.006. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
